bluuebunny/crossref_metadata_2025_split huggingface dataset:
In vitro investigation of the biological effects associated with human dermal fibroblasts exposed to 2.52 THz radiation
Authors: Wilmink Gerald J. , Rivest Benjamin D. , Roth Caleb C. , Ibey Bennett L. , Payne Jason A. , Cundin Luisiana X. , Grundt Jessica E. , Peralta Xomalin , Mixon Dustin G. , Roach William P. 
Published: August 2010

AbstractBackgroundTerahertz (THz) radiation sources are increasingly being used in military, defense, and medical applications. However, the biological effects associated with this type of radiation are not well characterized. In this study, we evaluated the cellular and molecular response of human dermal fibroblasts exposed to THz radiation.MethodsIn vitro exposures were performed in a temperature‐controlled chamber using a molecular gas THz laser (2.52 THz, 84.8 mW cm−2, durations: 5, 10, 20, 40, or 80 minutes). Both computational and empirical dosimetric techniques were conducted using finite‐difference time‐domain (FDTD) modeling approaches, infrared cameras, and thermocouples. Cellular viability was assessed using conventional MTT assays. In addition, the transcriptional activation of protein and DNA sensing genes were evaluated using qPCR. Comparable analyses were also conducted for hyperthermic and genotoxic positive controls.ResultsWe found that cellular temperatures increased by 3°C during all THz exposures. We also found that for each exposure duration tested, the THz and hyperthermic exposure groups exhibited equivalent levels of cell survival (≥90%) and heat shock protein expression (∼3.5‐fold increases). In addition, the expression of DNA sensing and repair genes was unchanged in both groups; however, appreciable increases were observed in the genotoxic controls.ConclusionsHuman dermal fibroblasts exhibit comparable cellular and molecular effects when exposed to THz radiation and hyperthermic stress. These findings suggest that radiation at 2.52 THz generates primarily thermal effects in mammalian cells. Therefore, we conclude that THz‐induced bioeffects may be accurately predicted with conventional thermal damage models. Lasers Surg. Med. 42:152–163, 2011 © 2010 Wiley‐Liss, Inc.
The Matrix‐Binding Domain of Microfibril‐Associated Glycoprotein‐1 Targets Active Connective Tissue Growth Factor to a Fibroblast‐Produced Extracellular Matrix
Authors: Weinbaum Justin S. , Tranquillo Robert T. , Mecham Robert P. 
Published: August 2010

AbstractIt is advantageous to use biomaterials in tissue engineering that stimulate extracellular matrix (ECM) production by the cellular component. Connective tissue growth factor (CTGF) stimulates type I collagen (COL1A1) transcription, but is functionally limited as a free molecule. Using a matrix‐binding domain (MBD) from microfibril‐associated glycoprotein‐1, the fusion protein MBD–CTGF was targeted to the ECM and tested for COL1A1 transcriptional activation. MBD–CTGF produced by the ECM‐synthesizing fibroblasts, or provided exogenously, localized to the elastic fiber ECM. MBD–CTGF, but not CTGF alone, led to a two‐fold enhancement of COL1A1 expression. This study introduces a targeting technology that can be used to elevate collagen transcription in engineered tissues and thereby improve tissue mechanics.magnified image
Establishment of an orthotopic transplantable gastric cancer animal model for studying the immunological effects of new cancer therapeutic modules
Authors: Shan Yan‐Shen , Fang Jung‐Hua , Lai Ming‐Derg , Yen Meng‐Chi , Lin Pin‐Wen , Hsu Hui‐Ping , Lin Chian‐Yuh , Chen Yi‐Ling 
Published: August 2010

AbstractTumor cell growth is influenced by the cellular microenvironment including the presence of immune cells and blood vessels. Currently, no transplantable gastric cancer syngeneic animal models exist; therefore, we set out to establish a mouse gastric carcinoma cell line, which was named mouse gastric carcinoma cell line 3I (MGCC3I), from forestomach carcinoma developed in benzo[a]pyrene‐treated ICR mice. MGCC3I cells showed epithelial‐like morphology, multinuclear giant cell formation, and retained an intestinal phenotype, which are similar to human gastric cancer carcinoma cells. The expression of gastric cancer markers MUC1, MUC2, and MUC5AC, and oncogenes c‐myc, c‐met, cyclin E1, and cancer stem cell marker CD44 was determined in MGCC3I cells. MGCC3I cells formed poorly differentiated stomach tumors following orthotopic implantation into the stomachs of syngeneic ICR mice. Histone deacetylase inhibitors are recognized as a new class of anticancer drugs. The immunological therapeutic effects of the histone deacetylase inhibitors sodium butyrate and valproic acid were evaluated in this new animal tumor model. Sodium butyrate inhibited MGCC3I stomach tumor formation in animal models. Increased tumor infiltration by CD8 T cells and neutrophils was observed in mice treated with sodium butyrate or valproic acid. Depletion of CD8 T cells significantly attenuated tumor regression mediated by histone deacetylase inhibitors, which is correlated with enhancement of the MHC class I pathway in MGCC3I cells. Taken together, we have successfully established an orthotopic transplantable gastric tumor animal model and demonstrated its usefulness in revealing the role of CD8 T cells in the therapeutic effects of sodium butyrate. © 2010 Wiley‐Liss, Inc.
Long‐term effects of coordinative training in degenerative cerebellar disease
Authors: Ilg Winfried , Brötz Doris , Burkard Susanne , Giese Martin A. , Schöls Ludger , Synofzik Matthis 
Published: August 2010

AbstractFew clinical studies have evaluated physiotherapeutic interventions for patients with degenerative cerebellar disease. In particular, evidence for long‐term effects and transfer to activities of daily life is rare. We have recently shown that coordinative training leads to short‐term improvements in motor performance. To evaluate long‐term benefits and translation to real world function, we here assessed motor performance and achievements in activities of daily life 1 year after a 4 week intensive coordinative training, which was followed by a home training program. Effects were assessed by clinical rating scales, a goal attainment score and quantitative movement analysis. Despite gradual decline of motor performance and gradual increase of ataxia symptoms due to progression of disease after 1 year, improvements in motor performance and achievements in activities of daily life persisted. Thus, also in patients with degenerative cerebellar disease, continuous coordinative training leads to long‐term improvements, which translate to real world function. © 2010 Movement Disorder Society
Prevalence and clinical profile of restless legs syndrome in Parkinson's disease
Authors: Verbaan Dagmar , van Rooden Stephanie M. , van Hilten Jacobus J. , Rijsman Roselyne M. 
Published: August 2010

AbstractParkinson's disease (PD) and restless legs syndrome (RLS) have a dopaminergic link. More insight in the clinical profile of RLS in patients with PD may benefit our understanding of this link. The aims of this study were to evaluate the frequency and clinical profile of RLS in a large cohort of PD patients. In 269 nondemented Caucasian PD patients, the four diagnostic criteria for RLS were administered by a RLS trained researcher. In patients with definite RLS, the severity of these symptoms was assessed. Furthermore, in all patients, relevant motor and nonmotor symptoms in PD were evaluated. Definite RLS was present in 11% of the patients. RLS patients were more often female (69% vs. 32%, P < 0.001), but no other significant differences existed between PD patients with and without RLS. Within the PD patients with RLS, severity of RLS correlated positively with PD severity, motor fluctuations, depressive symptoms, daytime sleepiness, cognitive problems, autonomic symptoms, and psychotic symptoms. This study in a large PD cohort shows that prevalence of RLS is similar to that in the general population, which might be caused by underestimation of RLS due to dopaminergic treatment. No relations were found between the presence of RLS and PD symptoms, but the severity of RLS was related to the severity of PD‐related, mainly nondopaminergic, symptoms. It is hypothesized that, nondopaminergic systems, such as the noradrenergic system may play a role in the possible link between PD and RLS. © 2010 Movement Disorder Society
Psychiatric symptoms associated with focal hand dystonia
Authors: Voon Valerie , Butler Tracy R. , Ekanayake Vindhya , Gallea Cecile , Ameli Rezvan , Murphy Dennis L. , Hallett Mark 
Published: August 2010

AbstractMyoclonus dystonia and idiopathic dystonia are associated with a greater frequency of obsessive compulsive disorder (OCD) and major depression. We investigated the frequency of OCD in 39 patients with primary focal hand dystonia (FHD) using a semistructured interview. OCD and subsyndromal OCD was diagnosed in 5 of 39 (12.82%) patients with FHD, whereas OCD occurs in 2.3% of the general population. Recurrent depression occurred in (7 of 39) 17.95% of patients with FHD along with a family history of depression in (16 of 39) 41.02%. Overlapping mechanisms manifesting as FHD may also predispose to OC symptoms and likely implicates a common striatal dysfunction. © 2010 Movement Disorder Society
Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications
Authors: Naumann Markus , Carruthers Alastair , Carruthers Jean , Aurora Sheena K. , Zafonte Ross , Abu‐Shakra Susan , Boodhoo Terry , Miller‐Messana Mary Ann , Demos George , James Lynn , Beddingfield Frederick , VanDenburgh Amanda , Chapman Mary Ann , Brin Mitchell F. 
Published: August 2010

AbstractThis meta‐analysis evaluated the frequency of neutralizing antibody (nAb) conversion with onabotulinumtoxinA (BOTOX®; Allergan) across five studied indications. The analysis was based on large, controlled or prospective, open‐label trials (durations 4 months to ≥2 years). Serum samples were analyzed for nAbs using the Mouse Protection Assay. Subjects who were antibody negative at baseline and had at least one analyzable postbaseline antibody assay result were included. The 16 clinical studies included 3,006 subjects; of these, 2,240 met the inclusion criteria for this analysis. Subjects received 1–15 treatments (mean 3.8 treatments) with onabotulinumtoxinA. Total doses per treatment cycle ranged from 10 or 20 units in glabellar lines to 20–500 units in cervical dystonia. The numbers of subjects who converted from an antibody‐negative status at baseline to antibody‐positive status at any post‐treatment time point were: cervical dystonia 4/312 (1.28%), glabellar lines 2/718 (0.28%), overactive bladder 0/22 (0%), post‐stroke spasticity 1/317 (0.32%), and primary axillary hyperhidrosis 4/871 (0.46%). Across all indications, 11/2,240 subjects (0.49%) converted from antibody negative at baseline to positive at one or more post‐treatment time points, but only three subjects became clinically unresponsive to onabotulinumtoxinA at some point following a positive assay. Based on these large trials, the frequency of antibody conversion after onabotulinumtoxinA treatment is very low, and infrequently leads to loss of efficacy. © 2010 Movement Disorder Society
Restless legs syndrome and Parkinson's disease in men
Authors: Gao Xiang , Schwarzschild Michael A. , O'Reilly Eilis J. , Wang Hao , Ascherio Alberto 
Published: August 2010

AbstractWe examined whether men with restless legs syndrome (RLS) have a higher prevalence of Parkinson's disease (PD) among 23,119 US participants of the Health Professional Follow‐up Study who were free of diabetes and arthritis. RLS was assessed using a set of standardized questions recommended by the International RLS Study Group. PD cases were identified by self‐reported questionnaires and confirmed by review of medical records. Compared to men without RLS, multivariate‐adjusted odds ratios for PD were 1.1 (95% confidence interval: 0.4, 3.0) for men with RLS symptoms 5–14 times per month and 3.09 (95% confidence interval: 1.5, 6.2; P trend = 0.003) for those with symptoms 15 times or more per month, after adjusting for age, smoking, use of antidepressant, and other covariates. In conclusion, men with RLS are more likely to have concurrent PD. Prospective studies are warranted to clarify the temporal relationship between RLS and PD. © 2010 Movement Disorder Society
Incidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders
Authors: Callaghan Russell C. , Cunningham James K. , Sajeev Gautam , Kish Stephen J. 
Published: August 2010

AbstractBecause methamphetamine exposure to experimental animals can damage brain dopamine neurones, we examined whether hospital patients diagnosed with methamphetamine‐related disorders might have greater risk of subsequent admission with a Parkinson's disease diagnosis. This was a population‐based cohort study using all statewide inpatient hospital discharge records from July 1, 1990, through June 30, 2000, in California, USA, in which subjects aged at least 50 years were followed for up to 10 years. Individuals with reported methamphetamine‐related conditions (n = 1,863; ICD‐9 codes 304.4, 305.7, 969.7, and E854.2) were matched on demographic variables and follow‐up time with those with primary appendicitis conditions (n = 9,315). The appendicitis group had a Parkinson's disease incidence rate no different than the rate found among members of a large health maintenance organization in California. Cox regression procedures were used to estimate group differences in the rates of receiving a subsequent inpatient diagnosis of Parkinson's disease (ICD‐9 332.0). The methamphetamine group showed increased risk of a subsequent admission with Parkinson's disease compared with that of the matched appendicitis group (adjusted hazard ratio = 2.65, 95% CI, 1.17–5.98, P= 0.019). Study limitations include a population limited to hospital admissions, an uncertainty regarding diagnostic validity of the ICD‐9 code 332.0 (Parkinson's disease), and a small number of incident cases with suspected Parkinson's disease. We strongly emphasize the preliminary nature of the findings. Nevertheless, these data, requiring replication, provide some evidence that methamphetamine users might be at greater than normal risk for developing Parkinson's disease. © 2010 Movement Disorder Society
The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: A randomized, double‐blind, placebo‐controlled study
Authors: Pal Endre , Nagy Ferenc , Aschermann Zsuzsanna , Balazs Eva , Kovacs Norbert 
Published: August 2010

AbstractBased on several open‐label and case studies, repetitive transcranial magnetic stimulation (rTMS) seems to have an antidepressive effect on patients with Parkinson's disease (PD). However, this hypothesis requires further confirmation. We conducted a randomized, double‐blind placebo‐controlled study to evaluate the effect of rTMS over the left dorsolateral prefrontal cortex (DLPFC) on depression and various motor and nonmotor features of PD. Twenty‐two PD patients with mild or moderate depressive episodes were assigned into two groups, one receiving real‐rTMS (90% of resting motor threshold, 5 Hz, 600 pulses‐a‐day for 10 days) over the left DLPFC, and another group receiving sham‐rTMS. An investigator blinded to the treatment performed three video‐taped examinations on each patient: before stimulation (baseline), 1 day (short term), and 30 days after treatment session ended (long‐term effect). Mini‐Mental State Examination, Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn‐Yahr, Epworth Sleepiness, Visual Analog and Montgomery‐Asberg Depression Rating Scales (MADRS), Beck Depression Inventory (BDI), and Trail making and Stroop tests were applied. In the actively treated group, not only depression rating scales showed significant improvement 30 days after treatment ended (BDI by 44.4% and MADRS by 26.1%), but also the accuracy of Stroop test (by 16%). We could also demonstrate an insignificant improvement in UPDRS‐III by 7.5 points (31.9%, P = 0.06). In the sham‐treated group none of the examined tests and scales improved significantly after sham stimulation. Our study demonstrated the beneficial effect of the left DLPFC rTMS on depression in PD lasting at least 30 days after treatment. However, this result should be confirmed in patients with severe depression by further clinical trials. © 2010 Movement Disorder Society
Falls in Parkinson's disease: Kinematic evidence for impaired head and trunk control
Authors: Cole Michael H. , Silburn Peter A. , Wood Joanne M. , Worringham Charles J. , Kerr Graham K. 
Published: August 2010

AbstractChanges in stride characteristics and gait rhythmicity characterize gait in Parkinson's disease and are widely believed to contribute to falls in this population. However, few studies have examined gait in PD patients who fall. This study reports on the complexities of walking in PD patients who reported falling during a 12‐month follow‐up. Forty‐nine patients clinically diagnosed with idiopathic PD and 34 controls had their gait assessed using three‐dimensional motion analysis. Of the PD patients, 32 (65%) reported at least one fall during the follow‐up compared with 17 (50%) controls. The results showed that PD patients had increased stride timing variability, reduced arm swing and walked with a more stooped posture than controls. Additionally, PD fallers took shorter strides, walked slower, spent more time in double‐support, had poorer gait stability ratios and did not project their center of mass as far forward of their base of support when compared with controls. These stride changes were accompanied by a reduced range of angular motion for the hip and knee joints. Relative to walking velocity, PD fallers had increased mediolateral head motion compared with PD nonfallers and controls. Therefore, head motion could exceed “normal” limits, if patients increased their walking speed to match healthy individuals. This could be a limiting factor for improving gait in PD and emphasizes the importance of clinically assessing gait to facilitate the early identification of PD patients with a higher risk of falling. © 2010 Movement Disorder Society
A mouse model for sleeve gastrectomy: Applications for diabetes research
Authors: Schlager Avraham , Khalaileh Abed , Mintz Yoav , Gazala Mahmoud Abu , Globerman Anat , Ilani Nadav , Rivkind Avraham I. , Salpeter Seth , Dor Yuval , Zamir Gideon 
Published: August 2010

AbstractIntroduction.Discovery of enhanced glucose tolerance following bariatric surgery has sparked renewed interest in the investigation of unchartered underlying pathways of glucose homeostasis. Delineation of this pathway may ultimately be the first step in the creation of a novel therapy for type II diabetes. Nevertheless, the technical complexity and formidable nature of these surgeries coupled with the fragile nature of small rodents has made the creation of a mouse model to study these effects incredibly challenging. We have created a simplified sleeve gastrectomy mouse model to study the effects of bariatric surgery on glucose tolerance and beta cell proliferation.Methods.Nineteen mice were randomized to undergo either sleeve gastrectomy (SG) (9) or sham operation (SH) (10). Weight and serum glucose were measured three times weekly and serum insulin measurements and pancreatic harvest were performed at the time of sacrifice. Five mice from each group were sacrificed after one week and the remainder sacrificed after one month.Results.Survival of mice was 100% for both groups. The SG group demonstrated an initial drop in weight and serum glucose as compared to SH, which normalized by one month following surgery. Serum insulin levels and rate of beta cell proliferation were similar in both groups after one week and one month.Conclusion.The simplified sleeve gastrectomy is a technically straightforward, low‐mortality technique for creating a bariatric mouse model which most faithfully replicates bariatric surgery performed in humans. This model can be a valuable tool to investigate the glucose tolerance and beta cell effects of bariatric surgery. © 2010 Wiley‐Liss, Inc. Microsurgery, 2011.
Antegrade anterolateral thigh perforator flap advancement for soft‐tissue reconstruction of the knee: Case report
Authors: Fujiwara Takashi , Chen Chien‐Chang , Ghetu Nicolae , Jeng Seng‐Feng , Kuo Yur‐Ren 
Published: August 2010

AbstractReconstruction of soft‐tissue defects of the knee has always been a challenging task to the plastic surgeon. In some cases, local or regional flaps are too small or have limited arc of rotation for adequate coverage. Free flaps can be technically demanding and time consuming. We report for the first time an antegrade anterolateral thigh perforator flap advancement, used to reconstruct the knee soft tissue defect in a 54‐year‐old man. The operative procedure required skeletonizing the perforators of anterolateral thigh flap and advancing the flap in the defect. The postoperative course was uneventful with the patient returned to normal daily activity and full range of motion 3‐months postoperatively. The shorter operating time with decreased donor‐site morbidity make this flap as a valuable alternative for soft‐tissue reconstruction of the knee. © 2010 Wiley‐Liss, Inc. Microsurgery, 2010.
Composite skull and dura defect reconstruction using combined latissimus dorsi musculocutaneous and serratus anterior muscle‐rib free flap coupled with vascularized galea transfer: A case report
Authors: Lee Jing‐Wei , Hsueh Yuan‐Yu , Lee Jung‐Shun 
Published: August 2010

AbstractRecalcitrant epidural abscess following cranioplasty is a complicated problem, which becomes even more trying when large span of dura and skull bone are being replaced by alloplastic materials. A 22‐year‐old male underwent right fronto‐temporo‐parietal craniectomy and duroplasty with artificial dura graft after traumatic brain injury. Epidural abscesses recurred after cranioplasty with autologous bone graft as well as with a methyl methacrylate bone plate. The massive defects of both the dura and skull bone (15 × 9 cm) caused by radical debridement were reconstructed successfully with a combined free latissimus dorsi and serratus anterior myo‐osseous flap transfer plus galea flap transposition. Proper contour and adequate stability of the construct were maintained during 2‐year follow up without episodes of relapsing infection. © 2010 Wiley‐Liss, Inc. Microsurgery, 2010.